Progyny, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $PGNY in the last 7 days.
Progyny director Kevin K. Gordon sold 11,500 shares for $321,358 at $27.94 each. The stock rose 59% in six months. Progyny reported Q2 2026 earnings of $0.55 per share on $350.51M revenue, beating estimates. Citizens raised its price target to $33. Progyny maintains full-year guidance of $1.36B-$1.385B revenue and $2.04-$2.10 EPS.
GORDON KEVIN K sold 11,500 shares of Progyny, Inc. (PGNY) at $27.94 ($0.32M total) on 2026-09-10.
Progyny (PGNY) and other health insurers reported Q2 earnings, with revenues beating estimates by 2.8% but guidance below expectations. PGNY's revenue grew 5.3% YoY, missing EBITDA guidance. CVS Health (CVS) reported 7.3% YoY revenue growth, beating estimates. Molina Healthcare (MOH) saw a 4.8% YoY revenue decline. Alignment Healthcare (ALHC) grew 31.6% YoY, while Clover Health (CLOV) saw 55.6% YoY growth. Stocks have declined since earnings, except CLOV, which rose 4.3%.
Recent PGNY coverage spans earnings, financial news and insider activity.
In the last 30 days, PGNY insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($321K). The most active reporter was GORDON KEVIN K with 1 filing.
Insider sale may signal slight downside pressure.
The insider sale may signal reduced confidence, potentially pressuring the stock short-term.
Earnings miss on guidance drives downside risk.
Earnings beat with disappointing guidance likely pressures the stock further.
Guidance downgrade may pressure the stock short-term, but expansion into postpartum, menopause and other women's health services could support upside over the medium term.
AlphAI scores every news story that mentions PGNY with an AI model for sentiment and relevance, and aggregates insider trades from Progyny, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Progyny director Kevin K. Gordon sold 11,500 shares for $321,358 at $27.94 each. The stock rose 59% in six months. Progyny reported Q2 2026 earnings of $0.55 per share on $350.51M revenue, beating estimates. Citizens raised its price target to $33. Progyny maintains full-year guidance of $1.36B-$1.385B revenue and $2.04-$2.10 EPS.
1 min readGORDON KEVIN K sold 11,500 shares of Progyny, Inc. (PGNY) at $27.94 ($0.32M total) on 2026-09-10.
1 min readProgyny (PGNY) and other health insurers reported Q2 earnings, with revenues beating estimates by 2.8% but guidance below expectations. PGNY's revenue grew 5.3% YoY, missing EBITDA guidance. CVS Health (CVS) reported 7.3% YoY revenue growth, beating estimates. Molina Healthcare (MOH) saw a 4.8% YoY revenue decline. Alignment Healthcare (ALHC) grew 31.6% YoY, while Clover Health (CLOV) saw 55.6% YoY growth. Stocks have declined since earnings, except CLOV, which rose 4.3%.
3 min readCencora (COR) is down 6.7% since reporting Q2 earnings, trading at $97.38. Progyny (PGNY) reported $350.5M revenue, up 5.3% YoY, but missed EBITDA guidance, dropping 14.1% to $25.94. Humana (HUM) reported $40.87B revenue, up 26.2% YoY, beating estimates, and rose 5% to $407.96. Cigna (CI) reported $71.56B revenue, up 6.6% YoY, beating estimates, but fell 4% to $284.64.
3 min readProgyny (PGNY) presented at the Wells Fargo Healthcare Conference, noting seasonal August softness but expecting a September recovery. The company serves 7.2M lives, with a large addressable market. It adjusted 2024 guidance downward but emphasized long-term growth, new product lines, and strong cash flow. Management highlighted Progyny's leading position in fertility benefits and expansion into women's health. The stock is trading below its Fair Value, with a PEG ratio of 0.46, according to Inv
2 min readCitizens raised Progyny's (PGNY) price target to $33.00, up from $31.00, maintaining a Market Outperform rating. The stock is trading at $26.04, which is 10.3% undervalued according to its GF Value™ of $29.03. PGNY has a strong GF Score™ of 93/100, with high ratings in growth and valuation.
2 min readCVS Health (CVS) reported $106.1B revenue, up 7.3% YoY, beating estimates. UnitedHealth (UNH) reported $112B revenue, flat YoY, also beating estimates. Progyny (PGNY) reported $350.5M revenue, up 5.3% YoY, missing guidance. Molina Healthcare (MOH) reported $10.87B revenue, down 4.8% YoY, missing guidance. All stocks have declined since earnings.
3 min readHealthcare stocks have outperformed the S&P 500, but some companies face challenges. Bausch + Lomb (BLCO) has declining EPS and free cash flow margins. Envista (NVST) shows weak sales growth and profitability. Progyny (PGNY) struggles with unit sales and capital returns. All three trade at forward P/E ratios of 16.9x, 17.5x, and 11.8x respectively.
3 min readCVS Health (CVS) reported $106.1B revenue, up 7.3% YoY, beating estimates. Despite strong earnings, its stock fell 10.2% to $93.76. Progyny (PGNY) reported $350.5M revenue, up 5.3% YoY, but missed EBITDA guidance, causing a 15.3% stock drop to $25.58. Cencora (COR) reported $84.75B revenue, up 5.1% YoY, in line with expectations, with a 3.2% stock increase to $316.20. UnitedHealth (UNH) reported $112B revenue, flat YoY, beating estimates, but its stock fell 7.1% to $388.62.
3 min readWells Fargo initiated coverage of Progyny with an overweight rating and $37 price target, implying 45% upside. The analyst cited demographic trends, corporate wellness focus, and healthcare innovation as drivers. Progyny's market share growth, global expansion, and new offerings were highlighted. Nine of 11 analysts rate the stock a buy or strong buy, with shares up 13% over the past year.
2 min read
